Benitec Biopharma (BNTC) Cash from Investing Activities (2019 - 2025)
Benitec Biopharma (BNTC) has disclosed Cash from Investing Activities for 6 consecutive years, with -$6000.0 as the latest value for Q1 2025.
- Quarterly Cash from Investing Activities rose 96.65% to -$6000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was -$18000.0 through Jun 2025, up 89.94% year-over-year, with the annual reading at -$18000.0 for FY2025, 89.94% up from the prior year.
- Cash from Investing Activities hit -$6000.0 in Q1 2025 for Benitec Biopharma, up from -$12000.0 in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $141000.0 in Q2 2021 to a low of -$179000.0 in Q1 2024.
- Historically, Cash from Investing Activities has averaged -$14000.0 across 4 years, with a median of -$12500.0 in 2022.
- Biggest five-year swings in Cash from Investing Activities: skyrocketed 1184.62% in 2021 and later tumbled 109.22% in 2022.
- Year by year, Cash from Investing Activities stood at $141000.0 in 2021, then crashed by 109.22% to -$13000.0 in 2022, then rose by 7.69% to -$12000.0 in 2024, then skyrocketed by 50.0% to -$6000.0 in 2025.
- Business Quant data shows Cash from Investing Activities for BNTC at -$6000.0 in Q1 2025, -$12000.0 in Q4 2024, and -$179000.0 in Q1 2024.